Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative treatments for patients with serious immunological and rare diseases. The company aims to improve patient outcomes in immune-mediated conditions by creating novel biologic molecules that address significant unmet medical needs.
Vera's lead product, atacicept, is a human TACI-Fc fusion protein designed to treat IgA Nephropathy, a kidney disease driven by B cells. It is currently in late-stage clinical trials and is intended for at-home self-administration. Another key product, MAU868, is a monoclonal antibody that targets BK virus infections in kidney transplant patients, showing promising results in clinical trials. Vera Therapeutics serves a global patient population, emphasizing innovation in biologic therapies to set new standards of care for challenging diseases.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative treatments for patients with serious immunological and rare diseases. The company aims to improve patient outcomes in immune-mediated conditions by creating novel biologic molecules that address significant unmet medical needs.
Vera's lead product, atacicept, is a human TACI-Fc fusion protein designed to treat IgA Nephropathy, a kidney disease driven by B cells. It is currently in late-stage clinical trials and is intended for at-home self-administration. Another key product, MAU868, is a monoclonal antibody that targets BK virus infections in kidney transplant patients, showing promising results in clinical trials. Vera Therapeutics serves a global patient population, emphasizing innovation in biologic therapies to set new standards of care for challenging diseases.
Est Monthly Spend
Repeat Buy Rate
Direct Response
Est. Spend
Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.
